NASDAQ:HRTS Tema Heart & Health ETF (HRTS) Price, Holdings, & News $30.58 +0.41 (+1.36%) As of 03:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Heart & Health ETF (NASDAQ:HRTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HRTS alerts:Sign Up Key Stats Today's Range$30.25▼$30.5850-Day Range$27.45▼$30.7452-Week Range$25.32▼$35.53Volume4,309 shsAverage Volume8,858 shsMarket Capitalization$51.37 millionAssets Under Management$49.58 millionDividend Yield1.50%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema. Read More Tema Heart & Health ETF ExpensesTypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.56%0.54%0.53%Other Expenses0.00%0.57%0.56%0.52%0.56%Total Expense0.99%0.74%0.76%0.73%0.73%Fee Waiver-0.24%-0.76%-0.66%-0.50%-0.63%Net Expense0.75%0.60%0.63%0.63%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Heart & Health ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTS ETF News HeadlinesShort Interest in Tema Heart & Health ETF (NASDAQ:HRTS) Grows By 50,800.0%September 12, 2025 | americanbankingnews.comTEMA HEART & HEALTH ETF ETFs | Markets InsiderAugust 7, 2025 | markets.businessinsider.comThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.September 18 at 2:00 AM | Brownstone Research (Ad)Weight-Loss Drug ETFs Generate Skinnier Returns Than ExpectedJune 11, 2025 | finance.yahoo.comHRTS Tema Obesity & Cardiometabolic ETFApril 10, 2025 | seekingalpha.comHRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema Heart & Health ETF's stock was trading at $28.87 on January 1st, 2025. Since then, HRTS stock has increased by 5.9% and is now trading at $30.58. Who are Tema Heart & Health ETF's major shareholders? Top institutional shareholders of Tema Heart & Health ETF include Sterling Investment Advisors Ltd. (10.02%), Jane Street Group LLC (2.21%), Oliver Lagore Vanvalin Investment Group (1.73%) and Flow Traders U.S. LLC (1.09%). How do I buy shares of Tema Heart & Health ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Heart & Health ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Heart & Health ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Fund Details IssuerTema Global Fund NameTema Heart & Health ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings46 Fund Statistics Assets Under Management$49.58 million Average Daily Volume$0.00 Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume2 Put Options3 Call Options2 Short Interest50,900 shs Miscellaneous Outstanding Shares1,680,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 8.05%Abbott Laboratories (NYSE:ABT)Holding Weight: 4.64%UnitedHealth Group (NYSE:UNH)Holding Weight: 4.56%AstraZeneca PLCHolding Weight: 4.48%Roche (OTCMKTS:RHHBY)Holding Weight: 4.27%Boston Scientific (NYSE:BSX)Holding Weight: 3.86%AbbVie (NYSE:ABBV)Holding Weight: 3.50%Novo Nordisk A/SHolding Weight: 3.49%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.35%Thermo Fisher Scientific (NYSE:TMO)Holding Weight: 3.32%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe dollar is failing – here’s your escapeSilver’s 100X Run Is Coming? All gold bull markets follow the same pattern. First, gold moves up. Then majo...Golden Portfolio | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Heart & Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Heart & Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
